Bei Akademie registrieren

Thema: US92337F1075

covid-19-4987726_1280.jpg - Foto: THN
covid-19-4987726_1280.jpg - Foto: THN
VCYT, US92337F1075

Veracyte stock: Veracyte presents 401-patient Decipher evidence ...

Decipher covered 401 patients and 27,000 real-world cases. Veracyte stock has November 4 results scheduled and Q2 revenue of USD 150.3 million.

ad-hoc-news.de, 24.10.26 00:41 Uhr
trader-5129770_1920.jpg - Foto: THN
trader-5129770_1920.jpg - Foto: THN
VCYT, US92337F1075

Veracyte presents six ESMO studies before results for Veracyte ...

Six studies are set for ESMO on October 23, 2026. Veracyte stock trades at EUR 39.04 on October 20, 2026 during trading.

ad-hoc-news.de, 20.10.26 14:28 Uhr
stock-market-6531146_1920.jpg - Foto: THN
stock-market-6531146_1920.jpg - Foto: THN
VCYT, US92337F1075

Veracyte secures Medicare coverage: 11 analysts rate Veracyte ...

Prosigna gained Medicare coverage on October 16, 2026. For Veracyte stock, second-quarter revenue reached USD 150.32 million, up 15.5 percent year over year.

ad-hoc-news.de, 18.10.26 12:55 Uhr
thai-1549084_1920.jpg - Foto: THN
thai-1549084_1920.jpg - Foto: THN
VCYT, US92337F1075

Veracyte sets November 4 results date for Veracyte stock ...

Second-quarter revenue reached USD 150.3 million, up 15 percent year over year. Veracyte stock costs EUR 38.85 on October 15, 2026.

ad-hoc-news.de, 15.10.26 12:52 Uhr
new-york-stock-exchange-1708834_1920.jpg - Foto: THN
new-york-stock-exchange-1708834_1920.jpg - Foto: THN
VCYT, US92337F1075

Veracyte stock falls 4.64 percent as Decipher data draw ...

Veracyte stock carries a Q2 revenue base of USD 150.32 million, up 15.5 percent year over year. Eleven analysts set a Moderate Buy consensus and USD 55.78 average target.

ad-hoc-news.de, 06.10.26 16:34 Uhr
deal-4131445.jpg - Foto: THN
deal-4131445.jpg - Foto: THN
VERA, US92337F1075

Vera Therapeutics stock gains after fresh analyst support ...

Vera Therapeutics stock attracts investor attention as new analyst commentary highlights upside potential with recent clinical progress and cash reserves in focus for biotech ...

ad-hoc-news.de, 02.09.26 07:30 Uhr
gavel-7533906_1920.jpg - Foto: THN
gavel-7533906_1920.jpg - Foto: THN
VERA, US92337F1075

Vera Therapeutics stock (US92337F1075): shares consolidate ...

Vera Therapeutics shares on Nasdaq remain near recent highs after the United States biotech group’s May 2026 quarterly update and subsequent price gains as investors digest ...

ad-hoc-news.de, 01.06.26 19:56 Uhr
charts-6531107_1920.jpg - Foto: THN
charts-6531107_1920.jpg - Foto: THN
VERA, US92337F1075

Vera Therapeutics stock (US92337F1075): biotech name in ...

Vera Therapeutics has drawn investor attention following recent clinical and regulatory updates around its lead IgA nephropathy program. What is behind the story and how does ...

ad-hoc-news.de, 26.05.26 12:08 Uhr
apple-6498050_1920.jpg - Foto: THN
apple-6498050_1920.jpg - Foto: THN
VERA, US92337F1075

Vera Therapeutics stock (US92337F1075): clinical data and ...

Vera Therapeutics remains in focus after recent Phase 2 IgAN data and a solid cash position. What drives the story behind the Nasdaq-listed biotech – and what US investors ...

ad-hoc-news.de, 21.05.26 22:57 Uhr